Digital Thermal Monitoring for Endothelial Dysfunction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a device called Vendys II to assess blood vessel health in children and young adults undergoing hematopoietic cell transplantation (HCT). The device uses digital thermal monitoring to measure blood vessel response after temporarily restricting blood flow. The trial aims to determine if this method is feasible for children and young adults who are HCT candidates. Suitable participants are those aged 6-26 who are about to undergo or have recently undergone HCT. As an unphased trial, this study allows participants to contribute to innovative research that could enhance future HCT outcomes.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that the Vendys II device is safe for measuring vascular health?
Research has shown that the Vendys II device, used for checking blood flow, is safe. Studies with similar devices have reported no problems, indicating that people generally tolerate it well.
The FDA has approved the Vendys II, confirming it has passed safety tests for specific uses. As a noninvasive tool, it does not involve surgery or entering the body, making it safer than more invasive treatments.
Overall, evidence suggests that the Vendys II device is safe for measuring blood vessel health.12345Why are researchers excited about this trial?
Researchers are excited about the Vendys II Device because it offers a new, non-invasive way to assess blood vessel health by measuring temperature changes in the fingertips. Unlike traditional methods for evaluating endothelial dysfunction, which might require more invasive procedures or complex imaging, this device provides quick and easy monitoring. This approach helps in early identification of potential cardiovascular issues, potentially leading to better prevention strategies and personalized treatment plans.
What evidence suggests that the Vendys II device is effective for evaluating vascular health in children and adolescents undergoing HCT?
Studies have shown that the Vendys II device, used by participants in this trial, effectively measures blood vessel function, crucial for heart and blood health. This device assesses how blood vessels respond to changes in blood flow. It is fully automated and non-invasive, requiring no surgery or needles. Research indicates that it accurately measures changes in blood flow and vessel health. These findings suggest it could benefit patients undergoing treatments like hematopoietic cell transplantation, where monitoring blood vessel health is important.13467
Who Is on the Research Team?
Keri Schadler
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for children and young adults aged 6-26 who are about to undergo or have recently had a hematopoietic cell transplant (HCT). It includes both recipients within a month before/after HCT and healthy donors. Participants must fit the device on their index finger without pain or difficulty, consent to join, and not have skin toxicity or neuropathy affecting device use.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants undergo a single measurement of vascular health using the Vendys II device
Follow-up
Participants are monitored for any adverse events following the assessment
What Are the Treatments Tested in This Trial?
Interventions
- Vendys II Device
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor